I have a few concerns regarding the protocol. In the methods it appears that the patients are only followed for 48 hours. One of the composite end points is ileus, which usually does not surface until several days postoperatively. Please describe how you plan to assess for ileus. As part of the inclusion criteria, it appears that the operations will be fairly heterogeneous; however, one of the end points (ileus) is much more common with bowel operations. Will there be a subgroup analysis looking at operation type as a factor of these opioid related outcomes? Do you plan to adjust for multiple testing when considering the primary outcome measures separately? Please describe this in more detail.
REVIEWER
Rikke Nielsen, MD, PhD Dep Cardiothoracic Anesthesiology, Heart Centre, Rigshospitalet, University Hospital Copenhagen, Copenhagen, Denmark REVIEW RETURNED 24-Jan-2018
GENERAL COMMENTS
-There should be a defined time period for the study with estimated start and finish time.
-Will the study be reported in accordance with CONSORT? => We thank the reviewer for these remarks I have a few concerns regarding the protocol. In the methods it appears that the patients are only followed for 48 hours. One of the composite end points is ileus, which usually does not surface until several days postoperatively. Please describe how you plan to assess for ileus.
=> The objective is to assess whenever patient have their first flatus and/or stool. We hypothesized that patients in the OFA group would have the first flatus and/or stool sooner after surgery than patients receiving remifentanil during surgery.
As part of the inclusion criteria, it appears that the operations will be fairly heterogeneous; however, one of the end points (ileus) is much more common with bowel operations. Will there be a subgroup analysis looking at operation type as a factor of these opioid related outcomes?
=> As stated page 11 line 208, "Randomization will be stratified on the centre and on the type of surgery: abdominal (digestive, urological, gynaecological) or non abdominal."
Do you plan to adjust for multiple testing when considering the primary outcome measures separately? Please describe this in more detail.
=> The primary outcome will be analysed taking into account all components of the composite endpoint using a chi square test. A secondary exploratory analysis will be performed for each component of the primary endpoint taken separately without adjusting for multiple comparisons.
Following the reviewer's remark, this secondary analysis now appears as a secondary endpoint (see page 14, lines 266-270, and page 15, line 288).
Reviewer: 2:
=> We added the following sentence page 10, line 168: "The study started in December 2017 and the recruiting period will be 24 months."
-Will the study be reported in accordance with CONSORT?
=> Yes, it will. As requested by the editor I included a copy of the SPIRIT checklist Line 1: Title: the word prospective is unnecessary as it is a randomized controlled trial. depending on the surgical site) and 5% of postoperative delirium (from 3.6% to 30% expected after elective surgery and abdominal surgery, respectively). It is therefore more likely that we will observe more events than expected. In this case, 400 patients will allow us to detect a smaller difference between groups. For example, if the rate of events observed at the end of the study is 40% (30% expected), 400 patients will allow us to show a between-group difference of 33%. Furthermore, the primary endpoint is collected within 48h following surgery which makes the probability of dropouts very low.
Line 400: How long does the patient need to have a SAT <95%? Is one second enough?
=> In order to clarify we modified the following sentence page line 272: "Postoperative hypoxemia is defined as a SpO2 < 95% with a need for oxygen supplementation within the first 48h after extubation; the duration of oxygen treatment will also be recorded. as therapeutic oxygen supplementation to maintain SpO 2 > 95% within the first 48h after extubation; the duration of oxygen treatment will also be recorded." and reference # 27. 
VERSION 2 -REVIEW REVIEWER

GENERAL COMMENTS
The reviewer comments have been met and the protocol now describes the trial very accurately. I have only a minor comment and if this is specified in the protocol I would recommend acception. In the section "Allocation and Blinding" line 205: Please state if the randomization-code is computer generated and if it is blockrandomization.
VERSION 2 -AUTHOR RESPONSE
Reviewer1:
Please state any competing interests or state 'None declared': None declared => We stated or competing interests as "none declared"
The authors have adequately addressed my concerns from the initial review. The manuscript is much improved.
=> Thank you
Reviewer: 2
Please state any competing interests or state 'None declared':
=> We stated or competing interests as "none declared"
The reviewer comments have been met and the protocol now describes the trial very accurately. I have only a minor comment and if this is specified in the protocol I would recommend acception. In the section "Allocation and Blinding" line 205: Please state if the randomization-code is computer generated and if it is block-randomization.
=> We added the following sentence page 11: "Each patient will be given a unique patient-number and a randomisation number (patient code) will be computer generated. It will be a blockrandomisation."
